Abstract
Therapeutic communities have a long history, dating back to the Middle Ages. Beginning in the mid 20th century, the therapeutic community was revived in the form of such programs as Synanon, led by former substance abusers. Subsequent TCs have built upon the early principles of Synanon but adapted to meet the changing needs of clients and incorporated what has been learned from the expansion of the knowledge base of substance abuse treatment. Most notably, psychiatrists have come to play an important role as medical directors of TCs. This paper describes the adolescent treatment program at Daytop Village in terms of its functioning and patient population, and the role of the psychiatrist-medical director. Necessary adaptations to the TC model for adolescents are explained. The literature on outcome of this type of treatment with respect to adolescents is reviewed. The evidence suggests that therapeutic communities are an effective form of treatment for adolescent substance abusers.
Keywords: Adolescent substance abuse related disorders/treatment, therapeutic community, adolescents, residential treatment, Synanon, substance abusers, TCs, substance abuse treatment, adaptations, Daytop Village
Adolescent Psychiatry
Title: The Therapeutic Community for the Adolescent Substance Abuser
Volume: 1 Issue: 2
Author(s): Gregory C. Bunt and Britta Muehlbach
Affiliation:
Keywords: Adolescent substance abuse related disorders/treatment, therapeutic community, adolescents, residential treatment, Synanon, substance abusers, TCs, substance abuse treatment, adaptations, Daytop Village
Abstract: Therapeutic communities have a long history, dating back to the Middle Ages. Beginning in the mid 20th century, the therapeutic community was revived in the form of such programs as Synanon, led by former substance abusers. Subsequent TCs have built upon the early principles of Synanon but adapted to meet the changing needs of clients and incorporated what has been learned from the expansion of the knowledge base of substance abuse treatment. Most notably, psychiatrists have come to play an important role as medical directors of TCs. This paper describes the adolescent treatment program at Daytop Village in terms of its functioning and patient population, and the role of the psychiatrist-medical director. Necessary adaptations to the TC model for adolescents are explained. The literature on outcome of this type of treatment with respect to adolescents is reviewed. The evidence suggests that therapeutic communities are an effective form of treatment for adolescent substance abusers.
Export Options
About this article
Cite this article as:
C. Bunt Gregory and Muehlbach Britta, The Therapeutic Community for the Adolescent Substance Abuser, Adolescent Psychiatry 2011; 1 (2) . https://dx.doi.org/10.2174/2210676611101020122
DOI https://dx.doi.org/10.2174/2210676611101020122 |
Print ISSN 2210-6766 |
Publisher Name Bentham Science Publisher |
Online ISSN 2210-6774 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Calpain-1 and Calpain-2 in the Brain: Dr. Jekill and Mr Hyde?
Current Neuropharmacology Enzymatic Catalysis in Presence of Cyclodextrins
Current Organic Chemistry Role of Diagnostic Ultrasound in Patient Selection for Stroke Intervention
Recent Patents on CNS Drug Discovery (Discontinued) In Search of Reward Deficiency Syndrome (RDS)-Free Controls: The “Holy Grail” in Genetic Addiction Risk Testing
Current Psychopharmacology Pro-apoptotic Activity of BH3-only Proteins and BH3 Mimetics: from Theory to Potential Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Compound Libraries: Recent Advances and Their Applications in Drug Discovery
Current Drug Discovery Technologies A Novel Highly Selective Cannabinoid CB2 Agonist Reduces in vitro Growth and TGF-beta Release of Human Glial Cell Tumors
Central Nervous System Agents in Medicinal Chemistry Analysis of Glycosylation and Other Post-Translational Modifications by Mass Spectrometry
Current Analytical Chemistry Two -Year Efficacy and Safety of Botulinum a Toxin Intravesical Injections in Patients Affected by Refractory Painful Bladder Syndrome
Current Drug Delivery The Long Way to Objectify Organ Damage Related to Cocaine Abuse: Oxidative Stress is the Main Culprit
Mini-Reviews in Organic Chemistry Fibromyalgia
Current Rheumatology Reviews The Shock of the New: Progress in Schizophrenia Genomics
Current Genomics γ-Secretase as a Therapeutic Target for the Treatment of Alzheimers Disease
Current Pharmaceutical Design Distinct Functions of Retinoic Acid Receptor Beta Isoforms: Implications for Targeted Therapy
Endocrine, Metabolic & Immune Disorders - Drug Targets Functionalization of Phenols Using a Biomimetic Couple of Sodium Nitrite/Hydrogen Peroxide in an Acidic Medium
Current Organic Chemistry Crisis and the Neurobiology Involved in the Development of Consequent Mental Illness
Current Psychiatry Reviews Proposition of Potential GSK-3β Inhibitors for the Treatment of Alzheimer’s Disease: A Molecular Modeling Study
Current Computer-Aided Drug Design Solid Lipid Nanoparticles: A Potential Approach for Drug Delivery System
Nanoscience & Nanotechnology-Asia Approaches for the Development of Drugs for Treatment of Obesity and Metabolic Syndrome
Current Pharmaceutical Design Prediction of Affective Responses in Aerobic Exercise Sessions
CNS & Neurological Disorders - Drug Targets